Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans

Open access

Abstract

BACKGROUND: -adrenoreceptor antagonist, has been effective in alleviating nightmares associated with post-traumatic stress disorder (PTSD) in military veterans. METHODS: We recruited veterans from 13 Department of Veterans Affairs medical centers who had chronic PTSD and reported frequent nightmares. Participants were randomly assigned to receive prazosin or placebo for 26 weeks; the drug or placebo was administered in escalating divided doses over the course of 5 weeks to a daily maximum of 20 mg in men and 12 mg in women. After week 10, participants continued to receive prazosin or placebo in a double-blind fashion for an additional 16 weeks. The three primary outcome measures were the change in score from baseline to 10 weeks on the Clinician-Administered PTSD Scale (CAPS) item B2 ("recurrent distressing dreams"; scores range from 0 to 8, with higher scores indicating more frequent and more distressing dreams); the change in score from baseline to 10 weeks on the Pittsburgh Sleep Quality Index (PSQI; scores range from 0 to 21, with higher scores indicating worse sleep quality); and the Clinical Global Impression of Change (CGIC) score at 10 weeks (scores range from 1 to 7, with lower scores indicating greater improvement and a score of 4 indicating no change). RESULTS: A total of 304 participants underwent randomization; 152 were assigned to prazosin, and 152 to placebo. At 10 weeks, there were no significant differences between the prazosin group and the placebo group in the mean change from baseline in the CAPS item B2 score (between-group difference, 0.2; 95% confidence interval [CI], -0.3 to 0.8; P=0.38), in the mean change in PSQI score (between-group difference, 0.1; 95% CI, -0.9 to 1.1; P=0.80), or in the CGIC score (between-group difference, 0; 95% CI, -0.3 to 0.3; P=0.96). There were no significant differences in these measures at 26 weeks (a secondary outcome) or in other secondary outcomes. At 10 weeks, the mean difference between the prazosin group and the placebo group in the change from baseline in supine systolic blood pressure was a decrease of 6.7 mm Hg. The adverse event of new or worsening suicidal ideation occurred in 8% of the participants assigned to prazosin versus 15% of those assigned to placebo. CONCLUSIONS: In this trial involving military veterans who had chronic PTSD, prazosin did not alleviate distressing dreams or improve sleep quality. (Funded by the Department of Veterans Affairs Cooperative Studies Program; PACT ClinicalTrials.gov number, NCT00532493 .).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1507598

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 31 references

Research works printed but not linked: 3

  1. Guy W. CDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.
  2. Frisch MB. Manual and treatment guide for the Quality of Life Inventory (QOLI). Minneapolis: Pearson Assessments 1994.
  3. The Management of Posttraumatic Stress Disorder Working Group. VA/DoD clinical practice guideline for the management of posttraumatic stress disorder. Washington, DC: Department of Veterans Affairs, Department of Defense, 2010.

Cited by

See all 355

Metadata

Authors
Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., Romesser, J., Rosenheck, R., Shih, M.-C., Stein, M. B., Swift, R., Gleason, T., Lu, Y., & Huang, G. D.
Affiliations
  • University of Washington (US)
  • From the Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center (M.A.R., E.R.P., H.A.H., K.L.H., M.M.) and the Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine (M.A.R., E.R.P., M.M.), Seattle; VA Cooperative Studies Program Coordinating Center, Palo Alto (B.C., M.-C.S., Y.L.), VA Long Beach Healthcare System, Department of Human Behavior, University of California, Irvine (C.R.), the Department of Health Research...
  • Howard University (US)
  • United States Department of Veterans Affairs (US)
Venue
New England Journal of Medicine
Published
2018-02-08
Volume
378
Issue
6
Pages
507-517
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2789959403
Cited by
342
References
31
Citations by year
2026: 34 · 2025: 31 · 2024: 44 · 2023: 25 · 2022: 49 · 2021: 39 · 2020: 51 · 2019: 40 · 2018: 28
FWCI
46.32
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
VA Cooperative Studies Program.
Topics
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
Keywords
prazosin, post-traumatic stress disorder, military veterans, nightmares, chronic PTSD, alpha-blockers, sleep quality, blood pressure, adverse effects, PTSD pharmacotherapy, sleep disorders, sleep quality index, Clinician-Administered PTSD Scale, Clinical Global Impression of Change, dose escalation
MeSH terms
Adult, Combined Modality Therapy, Dose-Response Relationship, Drug, Double-Blind Method, Dreams, Female, Hospitals, Veterans, Humans, Male, Middle Aged, Prazosin, Psychiatric Status Rating Scales, Psychotherapy, Sleep, Sleep Wake Disorders, Stress Disorders, Post-Traumatic, United States, Veterans, Treatment Failure, Adrenergic alpha-1 Receptor Antagonists, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. https://app.cochat.ai/papers/10.1056/nejmoa1507598
The paper
Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., Romesser, J., Rosenheck, R., Shih, M.-C., Stein, M. B., Swift, R., Gleason, T., Lu, Y., & Huang, G. D. (2018). Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1507598

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.